IP Library Granted Patent US 10,858,635
Granted Patent B2
US 10,858,635 · App. 16/825,641 · Granted Dec 8, 2020

Biocatalysts and methods for the synthesis of substituted lactams

Inventors: Fabien Louis Cabirol (Dusseldorf, DE); Haibin Chen (Beijing, CN); Anupam Gohel (Bekasi, ID); Paulina Elena Salim (Singapore, SG); Derek J. Smith (Singapore, SG); Jacob Janey (New York, NY); Birgit Kosjek (Westfield, IN); Weng Lin Tang (Singapore, SG); Helen Hsieh (Singapore, SG); Son Q. Pham (Singapore, SG)
Assignee: Codexis, Inc.
C12N9/1096C07D211/76C12P13/001C12P13/005C12P17/12C12Y206/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,858,635
App. No.
16/825,641
Granted
Dec 8, 2020
Kind
B2
Abstract

The present disclosure relates to transaminase polypeptides capable of aminating a dicarbonyl substrate, and polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides.

Claims (19)

1. An engineered transaminase polypeptide comprising an amino acid sequence having at least 80% sequence identity to reference sequence SEQ ID NO:4 and at least an amino acid residue difference as compared to SEQ ID NO:4 at residue position X323.

2. The engineered polypeptide of claim 1 , in which X323 is C.

3. The engineered polypeptide of claim 2 , wherein the amino acid sequence further comprises one or more residue differences as compared to SEQ ID NO:4 selected from: X42G; X54P; X54R; X69A; X69G; X69T; X122M; X124F; X124L; X124N; X124R; X126A; X126T; X150S; X152C; X152G; X1521; X152L; X1525; X156A; X1565; X156T; X157L; X165N, X192A, X193G, X192H, X192K, X192N, X193Q, X192R, and X1925.

4. The engineered polypeptide of claim 2 , wherein the amino acid sequence further comprises a combination of residue differences selected from:

(a) X124W and X327L;

(b) X209M and X300G;

(c) X122F, X223V and X284A;

(d) X192A, X215H and X311T;

(e) X62N, X124F, X126A and X136L;

(f) X124W, X126A, X136L, X192A and X284A; and

(g) X124W, X126A, X136L, X152R/X152L/X1521, and X192A.

5. The engineered polypeptide of claim 1 , in which the amino acid sequence further comprises a residue difference as compared to SEQ ID NO:4 of X284A.

6. An engineered polynucleotide encoding the polypeptide of claim 1 .

7. A vector comprising the polynucleotide of claim 6 .

8. A host cell comprising the vector of claim 7 .

9. A method of converting compound 2 to compound 1,

comprising contacting compound 2 with the engineered polypeptide of claim 1 , under suitable reaction conditions to produce compound 1.

10. A method of converting compound 2 to compound 1d and compound 1a

comprising contacting compound 2 with the engineered polypeptide of claim 1 , under suitable reaction conditions to produce compound 1d and 1a, under suitable reaction conditions wherein said engineered polypeptide comprises at least 1.5 fold the activity of SEQ ID NO:4.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (5)
Division 15449677 · Mar 3, 2017
Division 14799180 · Jul 14, 2015
Division 14342713
Provisional Application 61532259 · Sep 8, 2011
Related Publication 20200231945A1 · Jul 23, 2020